shutterstock

Galectin Therapeutics’ share value plummets by half after NASH drug failure

pharmafile | December 6, 2017 | News story | Research and Development Galectin Therapeutics, nash, pharma, trial failure 

Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis (NASH) cirrhosis, had missed its primary endpoint in a Phase 2b trial.

Specifically, while the galectin-3 inhibitor showed a positive trend in changing hepatic venous pressure gradients (HVPG) in patients, it failed to demonstrate this to a clinically significant degree. It was found that 44% of patients without oesophageal varices in the lower of the two dose groups examined showed a reduction of at least 2 mmHg versus baseline, while 15% showed the same improvement in the placebo group. Additionally, 40% in the low dose group demonstrated an at least 20% decline in HVPG from baseline, while 15% saw the same response in the placebo group.

However, despite the disappointing trial results, Galectin noted that could have clinical potential in NASH cirrhosis patients without oesophageal varices – a group which accounted for 50% of the 162 trial participants.  

Galectin CEO Peter Traber commented: “We believe that the results stratify a large and easily identifiable group of patients,” while Dr Stephen Harrison, one of trial’s lead investigators, added: “A therapy such as GR-MD-02 that could improve portal hypertension and potentially prevent the development of oesophageal varices in NASH cirrhosis and subsequent complications would be clinically valuable.”

Matt Fellows

Related Content

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content